Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
MicroRNA-155 coordinates the immunological landscape within murine melanoma and correlates with immunity in human cancers
H. Atakan Ekiz, Thomas B. Huffaker, Allie H. Grossmann, W. Zac Stephens, Matthew A. Williams, June L. Round, Ryan M. O’Connell
H. Atakan Ekiz, Thomas B. Huffaker, Allie H. Grossmann, W. Zac Stephens, Matthew A. Williams, June L. Round, Ryan M. O’Connell
View: Text | PDF
Research Article Immunology Oncology

MicroRNA-155 coordinates the immunological landscape within murine melanoma and correlates with immunity in human cancers

  • Text
  • PDF
Abstract

miR-155 has recently emerged as an important promoter of antitumor immunity through its functions in T lymphocytes. However, the impact of T cell–expressed miR-155 on immune cell dynamics in solid tumors remains unclear. In the present study, we used single-cell RNA sequencing to define the CD45+ immune cell populations at different time points within B16F10 murine melanoma tumors growing in either wild-type or miR-155 T cell conditional knockout (TCKO) mice. miR-155 was required for optimal T cell activation and reinforced the T cell response at the expense of infiltrating myeloid cells. Further, myeloid cells from tumors growing in TCKO mice were defined by an increase in wound healing genes and a decreased IFN-γ–response gene signature. Finally, we found that miR-155 expression predicted a favorable outcome in human melanoma patients and was associated with a strong immune signature. Moreover, gene expression analysis of The Cancer Genome Atlas (TCGA) data revealed that miR-155 expression also correlates with an immune-enriched subtype in 29 other human solid tumors. Together, our study provides an unprecedented analysis of the cell types and gene expression signatures of immune cells within experimental melanoma tumors and elucidates the role of miR-155 in coordinating antitumor immune responses in mammalian tumors.

Authors

H. Atakan Ekiz, Thomas B. Huffaker, Allie H. Grossmann, W. Zac Stephens, Matthew A. Williams, June L. Round, Ryan M. O’Connell

×

Figure 6

miR-155 positively correlates with immune infiltration in human solid tumors.

Options: View larger image (or click on image) Download as PowerPoint
miR-155 positively correlates with immune infiltration in human solid tu...
(A) Mature miR-155 transcript reads per million in the log scale were plotted across TCGA cohorts. (B) Summary of differential upregulation of immune-associated genes in miR-155–high tumor subsets. The frequency at which the genes were found to be upregulated across TCGA tumors is plotted. (C) Summary of top GSEA results from miR-155–high subsets of TCGA tumors. Color scale indicates the cumulative normalized enrichment score (NES) across 30 TCGA cohorts. (D) PCA of immune-associated gene expression using miR-155–high versus miR-155–low subsets of TCGA tumors. Data from 30 different TCGA cohorts were aggregated, resulting in 6,414 patients (3,201 belonging to miR-155–high subset and 3,213 belonging to miR-155–low subset). A total of 2,038 genes with human “immune process” GO annotation were used for this analysis. Separation of red and blue points indicates that miR-155–high tumors have a shared immune-related gene expression profile that is distinct from miR-155–low tumors across TCGA data sets. (E) PCA of TCGA tumor samples by using all shared genes in RNAseq data sets (15,151 genes analyzed). (F) Scatter plot showing an inverse correlation between the univariate Cox proportional hazard ratio (HR) of miR-155 and the average levels of miR-155 expression in TCGA tumors. Dashed line denotes HR of 1, which indicates no effect on survival. Red color gradient indicates the median genomic mutational burden in these tumors. High mutational burden was found to be loosely associated with a lower HR (i.e., improved clinical outcome). BLCA, bladder urothelial carcinoma; LGG, brain lower grade glioma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; READ, rectal adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; UCEC, uterine corpus endometrial carcinoma.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts